Compare CLST & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLST | MAIA |
|---|---|---|
| Founded | 1922 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 44.9M |
| IPO Year | N/A | 2022 |
| Metric | CLST | MAIA |
|---|---|---|
| Price | $15.03 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.6K | ★ 446.4K |
| Earning Date | 01-22-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $11,340,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.23 | ★ N/A |
| Revenue Growth | ★ 133.67 | N/A |
| 52 Week Low | $10.67 | $0.87 |
| 52 Week High | $15.30 | $2.74 |
| Indicator | CLST | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 68.54 | 56.19 |
| Support Level | $15.00 | $1.07 |
| Resistance Level | $15.00 | $1.46 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 95.56 | 62.71 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.